Impact of Advanced Age on the Incidence of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stable Coronary Artery Disease in a Real-World Setting in Spain
González Juanatey, Carlos; Anguita-Sánchez, M.; Barrios, V.; Núñez-Gil, I.; Gómez-Doblas, J.J.; García-Moll, X.; Lafuente-Gormaz, C.; Rollán-Gómez, M.J.; Peral-Disdier, V.; Martínez-Dolz, L.; Rodríguez-Santamarta, M.; Viñolas-Prat, X.; Soriano-Colomé, T.; Muñoz-Aguilera, R.; Plaza, I.; Curcio-Ruigómez, A.; Orts-Soler, E.; Segovia-Cubero, J.; Fanjul, V.; Marín-Corral, J.; Cequier, Á.

Identificadores
Identificadores
Visualización ou descarga de ficheiros
Visualización ou descarga de ficheiros
Data de publicación
2023Título da revista
Journal of Clinical Medicine
Tipo de contido
Artigo
Resumo
Patients with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) without myocardial infarction (MI) or stroke are at high risk for major cardiovascular events (MACEs). We aimed to provide real-world data on age-related clinical characteristics, treatment management, and incidence of major cardiovascular outcomes in T2DM-CAD patients in Spain from 2014 to 2018. We used EHRead® technology, which is based on natural language processing and machine learning, to extract unstructured clinical information from electronic health records (EHRs) from 12 hospitals. Of the 4072 included patients, 30.9% were younger than 65 years (66.3% male), 34.2% were aged 65-75 years (66.4% male), and 34.8% were older than 75 years (54.3% male). These older patients were more likely to have hypertension (OR 2.85), angina (OR 1.64), heart valve disease (OR 2.13), or peripheral vascular disease (OR 2.38) than those aged <65 years (p < 0.001 for all comparisons). In general, they were also more likely to receive pharmacological and interventional treatments. Moreover, these patients had a significantly higher risk of MACEs (HR 1.29; p = 0.003) and ischemic stroke (HR 2.39; p < 0.001). In summary, patients with T2DM-CAD in routine clinical practice tend to be older, have more comorbidities, are more heavily treated, and have a higher risk of developing MACE than is commonly assumed from clinical trial data.
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAttribution 4.0 International (CC BY 4.0)
